- Home
- ICU vs BFRI Comparison
ICU vs BFRI Comparison
Compare ICU & BFRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICU
- BFRI
- Stock Information
- Founded
- ICU 2018
- BFRI 1997
- Country
- ICU United States
- BFRI United States
- Employees
- ICU N/A
- BFRI N/A
- Industry
- ICU Biotechnology: Pharmaceutical Preparations
- BFRI Biotechnology: Pharmaceutical Preparations
- Sector
- ICU Health Care
- BFRI Health Care
- Exchange
- ICU Nasdaq
- BFRI Nasdaq
- Market Cap
- ICU 10.4M
- BFRI 8.7M
- IPO Year
- ICU N/A
- BFRI 2021
- Fundamental
- Price
- ICU $1.25
- BFRI $0.67
- Analyst Decision
- ICU
- BFRI Strong Buy
- Analyst Count
- ICU 0
- BFRI 1
- Target Price
- ICU N/A
- BFRI $7.00
- AVG Volume (30 Days)
- ICU 239.9K
- BFRI 92.3K
- Earning Date
- ICU 05-13-2025
- BFRI 05-14-2025
- Dividend Yield
- ICU N/A
- BFRI N/A
- EPS Growth
- ICU N/A
- BFRI N/A
- EPS
- ICU N/A
- BFRI N/A
- Revenue
- ICU $135,000.00
- BFRI $37,321,000.00
- Revenue This Year
- ICU $648.15
- BFRI $18.57
- Revenue Next Year
- ICU N/A
- BFRI $20.17
- P/E Ratio
- ICU N/A
- BFRI N/A
- Revenue Growth
- ICU N/A
- BFRI 9.54
- 52 Week Low
- ICU $1.21
- BFRI $0.65
- 52 Week High
- ICU $20.00
- BFRI $2.43
- Technical
- Relative Strength Index (RSI)
- ICU 30.70
- BFRI 25.40
- Support Level
- ICU $1.21
- BFRI $0.68
- Resistance Level
- ICU $2.57
- BFRI $0.96
- Average True Range (ATR)
- ICU 0.21
- BFRI 0.07
- MACD
- ICU -0.09
- BFRI -0.02
- Stochastic Oscillator
- ICU 2.94
- BFRI 1.48
About ICU SeaStar Medical Holding Corporation
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses.
About BFRI Biofrontera Inc.
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. Its licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. Its licensed product is Ameluz, which is a prescription drug approved for use in combination with the RhodoLED lamp series, for PDT (when used together, Ameluz PDT). including the complementary product BF-RhodoLED, and Xepi.